The biotechnology sector is undergoing significant transformation, driven by major technological advances and economic challenges. The "patent cliff," representing a potential loss of $400 billion, is pushing companies to innovate rapidly to offset patent losses. Artificial intelligence (AI) plays a crucial role in this transformation, facilitating drug discovery and optimizing research and development (R&D) processes. Recent fundraisings and strategic partnerships demonstrate the growing interest in AI within this sector.